Critical care medicine
-
Critical care medicine · Mar 2009
Comparative StudyInhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease.
To determine the effects of inhaled nitric oxide (NO) and aerosolized iloprost on pulmonary hemodynamics and lung edema formation in a rat model of pulmonary hypertension due to congestive heart failure (CHF). ⋯ Inhaled vasodilators may offer an effective, safe, and pulmonary-selective strategy for the treatment of pulmonary hypertension in left heart disease, and inhaled iloprost may be superior to NO in this condition.
-
Critical care medicine · Mar 2009
Demand flow facilitates spontaneous breathing during high-frequency oscillatory ventilation in a pig model.
Maintenance breathing is advocated in mechanical ventilation, which is difficult for the high-frequency oscillatory (HFO) ventilation. To facilitate spontaneous breathing during HFO ventilation, a demand flow system (DFS) was designed. The aim of the present study was to evaluate the system. ⋯ In moderately lung-injured anesthetized pigs during HFO ventilation, demand flow facilitated spontaneous breathing and augmented gas exchange. Demand flow decreased total breathing effort as quantified by PTP. Imposed work caused by the HFO ventilator appeared totally reduced by demand flow.
-
Critical care medicine · Mar 2009
Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest.
Lipid emulsion infusion is an emerging antidotal therapy for toxin-induced cardiac arrest. To compare the efficacy of resuscitation from bupivacaine-induced asystole using lipid emulsion infusion vs. vasopressin, alone and with epinephrine. ⋯ Lipid emulsion in this rat model provides superior hemodynamic and metabolic recovery from bupivacaine-induced cardiac arrest than do vasopressors. Systolic pressure was not a useful metric in the vasopressor groups. Vasopressin was associated with adverse outcomes.
-
Critical care medicine · Mar 2009
Comment Letter Comparative StudyEvaluation of 30-day mortality of levosimendan versus enoximone.